Levy DI - Search Results

1

PODO: Trial Design: Phase 2 Study of PF-06730512 in Focal Segmental Glomerulosclerosis.

Beck LH Jr, Berasi SP, Copley JB, Gorman D, Levy DI, Lim CN, Henderson JM, Salant DJ, Lu W. Beck LH Jr, et al. Among authors: levy di. Kidney Int Rep. 2021 Apr 3;6(6):1629-1633. doi: 10.1016/j.ekir.2021.03.892. eCollection 2021 Jun. Kidney Int Rep. 2021. PMID: 34169203 Free PMC article.

2

A Retrospective Study of Clinical and Economic Burden of Focal Segmental Glomerulosclerosis (FSGS) in the United States.

Kalantar-Zadeh K, Baker CL, Copley JB, Levy DI, Berasi S, Tamimi N, Alvir J, Udani SM. Kalantar-Zadeh K, et al. Among authors: levy di. Kidney Int Rep. 2021 Aug 9;6(10):2679-2688. doi: 10.1016/j.ekir.2021.07.030. eCollection 2021 Oct. Kidney Int Rep. 2021. PMID: 34622107 Free PMC article.

3

Rationale for using centralized transduction inhibition assays in three phase 3 rAAV gene therapy clinical trials.

Schulz M, Bashirians G, Cheng SH, Levy DI, Lundie M, Wilcox L, Winburn I, Somanathan S. Schulz M, et al. Among authors: levy di. Mol Ther Methods Clin Dev. 2023 Oct 11;31:101119. doi: 10.1016/j.omtm.2023.101119. eCollection 2023 Dec 14. Mol Ther Methods Clin Dev. 2023. PMID: 37868207 Free PMC article. No abstract available.

4

Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy.

Schulz M, Levy DI, Petropoulos CJ, Bashirians G, Winburn I, Mahn M, Somanathan S, Cheng SH, Byrne BJ. Schulz M, et al. Among authors: levy di. Mol Ther. 2023 Mar 1;31(3):616-630. doi: 10.1016/j.ymthe.2023.01.010. Epub 2023 Jan 11. Mol Ther. 2023. PMID: 36635967 Free PMC article. Review.

5

Durability of transgene expression after rAAV gene therapy.

Muhuri M, Levy DI, Schulz M, McCarty D, Gao G. Muhuri M, et al. Among authors: levy di. Mol Ther. 2022 Apr 6;30(4):1364-1380. doi: 10.1016/j.ymthe.2022.03.004. Epub 2022 Mar 10. Mol Ther. 2022. PMID: 35283274 Free PMC article. Review.

6

Incremental health care resource utilization and expenditures associated with autosomal-dominant polycystic kidney disease.

Iyer NN, Vendetti NJ, Levy DI, Mardekian J, Mychaskiw MA, Thomas J 3rd. Iyer NN, et al. Among authors: levy di. Clinicoecon Outcomes Res. 2018 Oct 31;10:693-703. doi: 10.2147/CEOR.S167837. eCollection 2018. Clinicoecon Outcomes Res. 2018. PMID: 30464562 Free PMC article.

7

Kcne4 deletion sex- and age-specifically impairs cardiac repolarization in mice.

Crump SM, Hu Z, Kant R, Levy DI, Goldstein SA, Abbott GW. Crump SM, et al. Among authors: levy di. FASEB J. 2016 Jan;30(1):360-9. doi: 10.1096/fj.15-278754. Epub 2015 Sep 23. FASEB J. 2016. PMID: 26399785 Free PMC article.

8

Long-term evaluation of analytical methods used in sirolimus therapeutic drug monitoring.

Holt DW, Mandelbrot DA, Tortorici MA, Korth-Bradley JM, Sierka D, Levy DI, See Tai S, Horowitz GL. Holt DW, et al. Among authors: levy di. Clin Transplant. 2014 Feb;28(2):243-51. doi: 10.1111/ctr.12305. Epub 2014 Jan 30. Clin Transplant. 2014. PMID: 24476346

9

The membrane protein MiRP3 regulates Kv4.2 channels in a KChIP-dependent manner.

Levy DI, Cepaitis E, Wanderling S, Toth PT, Archer SL, Goldstein SA. Levy DI, et al. J Physiol. 2010 Jul 15;588(Pt 14):2657-68. doi: 10.1113/jphysiol.2010.191395. Epub 2010 May 24. J Physiol. 2010. PMID: 20498229 Free PMC article.

10

MiRP3 acts as an accessory subunit with the BK potassium channel.

Levy DI, Wanderling S, Biemesderfer D, Goldstein SA. Levy DI, et al. Am J Physiol Renal Physiol. 2008 Aug;295(2):F380-7. doi: 10.1152/ajprenal.00598.2007. Epub 2008 May 7. Am J Physiol Renal Physiol. 2008. PMID: 18463315 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

40 results

Search Page